Kristie L. Kahl

The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for 3 indications.

Durvalumab (Imfinzi) induced a clinically meaningful improvement in overall survival (OS) compared with placebo in patients with stage III, unresectable non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

In a recent survey, lung cancer survivors reported long-term symptoms, including shortness of breath, fatigue, short-term memory, and anxiety.

Brigatinib (Alunbrig) reduced the risk of disease progression or death by more than 50% compared to crizotinib (Xalkori) in adult patients with ALK-positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor.

In combination with the standard front-line chemotherapy regimen of carboplatin and etoposide, the addition of atezolizumab (Tecentriq) significantly prolonged survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

Children with pediatric posterior fossa tumors like medulloblastoma who are treated with radiotherapy may be less likely to recall specific details of events that occurred after treatmen.

A study published in Blood demonstrated the significant disparities found between insurance status and survival outcomes in patients of all ages with follicular lymphoma.

The Food and Drug Administration (FDA) granted priority review to pembrolizumab (Keytruda) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

The Food and Drug Administration (FDA) granted priority review to pembrolizumab (Keytruda) for the treatment of adults and children with recurrent locally advanced or metastatic Merkel cell carcinoma, a rare skin cancer.

A recent survey of physicians revealed that 17% of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.

Patients who report higher satisfaction with their physicians’ communication with them also were more likely to receive more efficient care with fewer office visits and better health outcomes at lower costs.

A year after the first CAR T-cell therapy was approved to treat pediatric patients with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), researchers have issued guidelines to help healthcare professionals recognize and treat the associated adverse events (AEs) from this treatment.

Physicians’ Education Resource (PER)® set to host 2nd Annual School of Nursing Oncology™ from August 3 through 4 in Chicago.

The Food and Drug Administration approved filgrastim-aafi (Nivestym), a biosimilar to filgrastim (Neupogen), for all eligible indications of the original product.

Treatment with niraparib (Zejula) demonstrated durable responses among women with relapsed or refractory ovarian cancer regardless of BRCA mutation, study shows.

Not enough discussions are occurring between oncologists and patients with advanced cancer around goals of care.

Based on the identification of 6 gene variations that make carriers susceptible to developing medulloblastoma and possibly other cancers, researchers have proposed subgroup-based counseling and screening recommendations.

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis, according to phase III study results presented at the 2018 ASCO Annual Meeting.

The FDA granted a priority review to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of previously treated patients with advanced hepatocellular carcinoma.

Troubling statistics indicate that women who have head and neck cancer have worse out comes than their male counterparts.

The American Cancer Society recently updated its guidelines to lower the age to start colorectal cancer screening to 45. Nurses will play a vital role in implementing this important change.

The FDA granted a priority review to the anti-PD-1 agent pembrolizumab (Keytruda) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.

The FDA granted a priority review to a new drug application for glasdegib, an investigational oral smoothened inhibitor, for the treatment of adult patients with previously untreated acute myeloid leukemia in combination with low-dose cytarabine, a type of chemotherapy.

The FDA granted priority review to a supplemental Biologics License Application for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for an expanded age indication,

An off-the-shelf, dual-targeted chimeric antigen receptor (CAR) T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.

The FDA approved sargramostim (Leukine) for the treatment of adult and pediatric with hematopoietic subsyndrome of acute radiation syndrome (H-ARS).

The FDA approved pegfilgrastim-jmdb (Fulphila) as the first biosimilar to pegfilgrastim (Neulasta), a drug designed to reduce the risk of febrile neutropenia in patients treated with chemotherapy in certain types of cancer, according to a press release issued by the FDA.

Oncology nurses play an important role in educating patients with chronic lymphocytic leukemia (CLL) about the adverse effects (AEs) associated with ibrutinib (Imbruvica) treatment.

A symptom assessment app used at home may empower education and self-management among patients, and help with clinician communication.

While the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) shows promise for a subgroup of patients with metastatic colorectal cancer (mCRC), 32% still experienced a treatment-related adverse effect.